Patent · US Active

Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

US12168045B2 · kind B2 · utility

0Cited by

6References

32Claims

0Family size

Assignee

Ultimovacs ASA · NO

Inventors

Gustav Gaudernack · Sandvika, NO
Audun Tornes · Oslo, NO

Key dates

Filing date	Aug 9, 2022
Grant date	Dec 17, 2024
Priority date	—
Expiry date	Aug 9, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.